Artículos de revistas
Quality Of Life Of Chronic Myeloid Leukemia Patients In Brazil: Ability To Work As A Key Factor
Registro en:
Supportive Care In Cancer. Springer Verlag, v. 22, n. 8, p. 2113 - 2118, 2014.
9414355
10.1007/s00520-014-2196-1
2-s2.0-84905119542
Autor
Hamerschlak N.
De Souza C.
Cornacchioni A.L.
Pasquini R.
Tabak D.
Spector N.
Steagall M.
Institución
Resumen
Purpose: The purpose of this study was to evaluate the quality of life (QOL) of patients receiving treatment by the public health system in Brazil for chronic myeloid leukemia (CML), a disease requiring daily and strict compliance to oral medication and regular blood and bone marrow controls, which are invasive exams. Methods: Between 2008 and 2010, patients with CML were surveyed by telephone. Quality of life was evaluated by the functional assessment of chronic illness therapy (FACIT) tool. Results: The mean QOL among CML patients was 92.53 (out of 124 total points) in the trial outcome index, 78.50 (out of 108) in the general total score, and 130.43 (out of 176) in the leukemia total score. Patients who had the prescriptions recently changed anyway had better QOL general score (p=0.012) and leukemia-specific score (p=0.043) than those who remained with the same treatment. Imatinib was not associated with this change in QOL (p>0.797). The more the patient felt able to work, the higher the scores in all three FACIT scales (p<0.001, Spearman's correlation). The use of imatinib (p=0.012) was associated with a better ability to work, while chemotherapy (p=0.017) and the use of hydroxyurea (p=0.001) were inversely associated with work capability. Conclusions: A recent change in medication can improve quality of life. The ability to work is an important component of quality of life of patients with CML. Ability to work should be specifically considered in CML treatment. © 2014 Springer-Verlag. 22 8 2113 2118 Saussele, S., Lauseker, M., Gratwohl, A., Beelen, D.W., Bunjes, D., Schwerdtfeger, R., Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: Evaluation of its impact within a subgroup of the randomized German CML Study IV (2010) Blood, 115 (10), pp. 1880-1885 Lee, S.J., Kukreja, M., Wang, T., Giralt, S.A., Szer, J., Arora, M., Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia (2008) Blood, 112 (8), pp. 3500-3507 Dowling, M., Meenaghan, T., Kelly, M., Treating chronic myeloid leukaemia: NICE guidance (2012) Br J Nurs, 21 (4), pp. S16-S17 Dobbin, J.A., Gadelha, M.I.P., Imatinib Mesylate in the treatment of chronic myelogenous leukemia (2002) Rev Bras Cancerol, 48 (3), pp. 429-438 Hahn, E.A., Glendenning, G.A., Sorensen, M.V., Hudgens, S.A., Druker, B.J., Guilhot, F., Larson, R.A., Cella, D., Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS study (2003) Journal of Clinical Oncology, 21 (11), pp. 2138-2146. , DOI 10.1200/JCO.2003.12.154 Efficace, F., Cocks, K., Breccia, M., Sprangers, M., Meyers, C.A., Vignetti, M., Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: Inclusion of quality of life and other patient-reported outcomes (2012) Crit Rev Oncol Hematol, 81 (2), pp. 123-135 Hamerschlak, N., Pietrocola, M., Tabak, D., Lerner, D., Chiattone, C., Hungria, V., Treatment of accelerated (AP) and blastic phase (BP) of Philadelphia (Ph) chromosome positive chronic myeloid leukemia (CML) with imatinib (2003) Proc Am Soc Clin Oncol, 22 (ABSTR 2479). , http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview= abst_detail_view&confID=23&abstractID=103947, Available from: Accessed in 2012 (Aug 28) Cortes, J., De Souza, C., Ayala-Sanchez, M., Bendit, I., Best-Aguilera, C., Enrico, A., Current patient management of chronic myeloid leukemia in Latin America: A study by the Latin American Leukemia Net (LALNET) (2010) Cancer, 116 (21), pp. 4991-5000 Saglio, G., Kim, D.W., Issaragrisil, S., Le Coutre, P., Etienne, G., Lobo, C., Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia (2010) N Engl J Med, 362 (24), pp. 2251-2259 Kantarjian, H., Shah, N.P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia (2010) N Engl J Med, 362 (24), pp. 2260-2270 Kantarjian, H., Shah, N.P., Hochhaus, A., Cortes, J.E., Shah, S., Ayala, M., Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study (2010) Journal of Clinical Oncology, 28 (18 SUPPL.), pp. LBA6500. , http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/LBA6500, Available from: Accessed in 2012 (Aug 28) Saglio, G., Kim, D.W., Issaragrisil, S., Le Coutre, P., Etienne, G., Lobo, C., Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia (2010) N Engl J Med, 362 (24), pp. 2251-2259 Larson, R.A., Le Coutre, P.D., Reiffers, J., Hughes, T.P., Saglio, G., Edrich, P., Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year (2010) Journal of Clinical Oncology, 28 (15 SUPPL.), p. 6501. , http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/6501, Available from: Accessed in 2012 (Aug 28) Terasawa, T., Dahabreh, I., Trikalinos, T.A., BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors inpatients with chronic myeloid leukemia (2010) PLoS Curr, 2, pp. RRN1204. , Version 2 Pinilla-Ibarz, J., Cortes, J., Mauro, M.J., Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications (2011) Cancer, 117 (4), pp. 688-697 Jabbour, E., Cortes, J., Kantarjian, H., Long-term outcomes in the second-line treatment of chronic myeloid leukemia: A review of tyrosine kinase inhibitors (2011) Cancer, 117 (5), pp. 897-906 Iacobucci, I., Rosti, G., Amabile, M., Poerio, A., Soverini, S., Cilloni, D., Testoni, N., Martinelli, G., Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment (2006) Journal of Clinical Oncology, 24 (3), pp. 454-459. , DOI 10.1200/JCO.2005.03.2011 Quintás-Cardama, A., Kantarjian, H., Jones, D., Shan, J., Borthakur, G., Thomas, D., Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy (2009) Blood, 113 (25), pp. 6315-6321 Pellegrino, E.D., Is truth telling to the patient a cultural artifact? (1992) JAMA, 268 (13), pp. 1734-1735 Faria, S.L., Souhami, L., Communication with the cancer patient. Information and truth in Brazil (1997) Annals of the New York Academy of Sciences, 809, pp. 163-171 Gulinelli, A., Aisawa, R.K., Konno, S.N., Morinaga, C.V., Costardi, W.L., Antonio, R.O., Desire of information and participation in therapeutic decisions concerning severe diseases, in patients of a University Hospital (2004) Rev Assoc Med Bras, 50 (1), pp. 41-47 Rigatos, G.A., Cancer and truth-telling in Greece. Historical, statistical, and clinical data (1997) Ann N Y Acad Sci, 809, pp. 383-392 Hall, J.A., Roter, D.L., Katz, N.R., Meta-analysis of correlates of provider behavior in medical encounters (1988) Med Care, 26 (7), pp. 657-675 Da, S.C.H.M., Guerino, C.R.L., Borges, T.R., Marquez, C.T., Boaventura, D.A.C., Gontijo, D.G., Diniz, S.J., De Paula, R.L., Not telling the truth in the patient-physician relationship (2003) Bioethics, 17 (5-6), pp. 417-424 Suchman, A.L., Matthews, D.A., What makes the patient-doctor relationship therapeutic? Exploring the connexional dimension of medical care (1988) Annals of Internal Medicine, 108 (1), pp. 125-130 Farsi, Z., Nayeri, N.D., Negarandeh, R., The coping process in adults with acute leukemia undergoing hematopoietic stem cell transplantation (2012) J Nurs Res, 20 (2), pp. 99-109 Grant, M., Cooke, L., Williams, A.C., Bhatia, S., Popplewell, L., Uman, G., Forman, S., Functional status and health-related quality of life among allogeneic transplant patients at hospital discharge: A comparison of sociodemographic, disease, and treatment characteristics (2012) Support Care Cancer, 20 (11), pp. 2697-2704 Holloway, S., Lord, K., Bethelmie-Bryan, B., Shepard, M.W., Neely, J., McLemore, M., Managing chronic myeloid leukemia: A coordinated team care perspective (2012) Clin Lymphoma Myeloma Leuk, 12 (2), pp. 88-93 Yost, K.J., Sorensen, M.V., Hahn, E.A., Glendenning, G.A., Gnanasakthy, A., Cella, D., Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the functional assessment of cancer therapy-biologic response modifiers (FACT-BRM) instrument (2005) Value in Health, 8 (2), pp. 117-127. , DOI 10.1111/j.1524-4733.2005.08202.x Deininger, M.W., Chronic myeloid leukemia: An historical perspective (2008) Hematology Am Soc Hematol Educ Program, p. 418 Aziz, Z., Iqbal, J., Aaqib, M., Akram, M., Saeed, A., Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronicmyeloid leukemia (2011) Leuk Lymphoma, 52 (6), pp. 1017-1023 Efficace, F., Baccarani, M., Breccia, M., Alimena, G., Rosti, G., Cottone, F., Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population (2009) Blood, 118 (17), pp. 4554-4560 Phillips, K.M., Pinilla-Ibarz, J., Sotomayor, E., Lee, M.R., Jim, H.S., Small, B.J., Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A controlled comparison (2013) Support Care Cancer, 21 (4), pp. 1097-1103 Efficace, F., Baccarani, M., Breccia, M., Cottone, F., Alimena, G., Deliliers, G.L., Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib (2013) Leukemia, 27 (7), pp. 1511-1519 Efficace, F., Rosti, G., Cottone, F., Breccia, M., Castagnetti, F., Iurlo, A., Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors (2013) Leuk Res, , doi:10.1016/j.leukres.2013.07.003, [Epub ahead of print] PubMed PMID: 23906625 Efficace, F., Rosti, G., Aaronson, N., Cottone, F., Angelucci, E., Molica, S., Patient versus physician symptom and health status reporting in chronic myeloid leukemia (2013) Haematologica, 92 (1), pp. 22-24. , [Epub ahead of print] PubMed PMID: 24241488 Hirji, I., Gupta, S., Goren, A., Chirovsky, D.R., Moadel, A.B., Olavarria, E., Chronic myeloid leukemia (CML): Association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective (2013) Health Qual Life Outcome, 11, p. 167. , PubMed PMID: 24099272 Efficace, F., Cardoni, A., Cottone, F., Vignetti, M., Mandelli, F., Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: A systematic review (2013) Leuk Res, 37 (2), pp. 206-213 Hochhaus, A., O'Brien, S.G., Guilhot, F., Druker, B.J., Branford, S., Foroni, L., Six-year follow-up of patients receiving imatinib for the first-line treatment of chronicmyeloid leukemia (2009) Leukemia, 23 (6), pp. 1054-1061 De Almeida, M.H., Pagnano, K.B., Vigorito, A.C., Lorand-Metze, I., De Souza, C.A., Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: A Brazilian single-center cohort (2013) Acta Haematol, 130 (1), pp. 16-22 Webster, K., Cella, D., Yost, K., The functional assessment of chronic illness therapy (FACIT) measurement system: Properties, applications, and interpretation (2003) Health Qual Life Outcomes, 1, p. 79 Brucker, P.S., Yost, K., Cashy, J., Webster, K., Cella, D., General population and cancer patient norms for the functional assessment of cancer therapy-general (FACT-G) (2005) Evaluation and the Health Professions, 28 (2), pp. 192-211. , DOI 10.1177/0163278705275341 Efficace, F., Baccarani, M., Rosti, G., Cottone, F., Castagnetti, F., Breccia, M., Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: An observational patient-centered outcome study (2012) Br J Cancer, 107 (6), pp. 904-909 Jabbour, E., Saglio, G., Hughes, T.P., Kantarjian, H., Suboptimal responses in chronic myeloid leukemia: Implications and management strategies (2012) Cancer, 118 (5), pp. 1181-1191 Efficace, F., Breccia, M., Saussele, S., Kossak-Roth, U., Cardoni, A., Caocci, G., Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group (2012) Ann Hematol, 91 (9), pp. 1371-1381